| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aktien New York: Zinsentscheidung der Fed belastet US-Aktien | 2.082 | dpa-AFX | NEW YORK (dpa-AFX) - Die Zinsentscheidung der Fed hat die US-Börsen am Mittwoch belastet. Die Notenbank hatte ihre Leitzinsen wie erwartet unverändert gelassen. Der Leitindex Dow Jones Industrial gab... ► Artikel lesen | |
| Mi | Sanofi: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi | 508 | GlobeNewswire (Europe) | Annual General Meeting of April 29, 2026
Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened... ► Artikel lesen | |
| Mi | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale | 482 | PR Newswire | Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical... ► Artikel lesen | |
| 15:10 | KalVista Pharmaceuticals-Aktie: +270% nach sharedealsPlus-Tipp | 264 | sharedeals.de | Die Aktie des US-Biotechunternehmens KalVista Pharmaceuticals ist nach einer zuvor schon starken Performance gestern nochmal einmal um rund +40% explodiert. Grund ist eine milliardenschwere Übernahme:... ► Artikel lesen | |
| Mi | Autolus Therapeutics plc: Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction | 262 | GlobeNewswire (Europe) | Initiative focused on driving gross profit margin and path to profitability for the ALL businessCompany will reduce headcount by approximately 13% while doubling manufacturing of products for commercial... ► Artikel lesen | |
| 16:06 | Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA | 241 | AFX News | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| 13:10 | uniQure Inc.: uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease | 228 | GlobeNewswire (Europe) | ~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential... ► Artikel lesen | |
| 15:18 | Alnylam Reports Q1 Net Profit As Product Revenue Surges; Stock Up 8% In Pre-Market | 184 | AFX News | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc.(ALNY), an RNAi therapeutics company, on Thursday reported a net income for the first quarter of fiscal 2026, supported by a surge in revenue... ► Artikel lesen | |
| 13:06 | Novocure Reports First Quarter 2026 Financial Results | 184 | Business Wire | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| 12:02 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026 | 183 | ACCESS Newswire | RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March... ► Artikel lesen | |
| 13:06 | Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results | 130 | Business Wire | Presentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer Human imaging data provides further... ► Artikel lesen | |
| 03:00 | Mesoblast Limited: Mesoblast Reports Ryoncil Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million | 99 | GlobeNewswire (Europe) | Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| AMGEN | 296,20 | 8,27 | +2,79 % | 2,52 | 15.05.2026 | |
| ROYALTY PHARMA | 42,980 | 0,77 | +1,79 % | 0,24 | 15.05.2026 | |
| REGENERON PHARMACEUTICALS | 586,20 | 3,02 | +0,52 % | 0,94 | 20.02.2026 | |
| IONIS PHARMACEUTICALS | 64,22 | 0,00 | 0,00 % | |||
| BIOGEN | 165,68 | 0,00 | 0,00 % | |||
| VERA THERAPEUTICS | 35,610 | 0,00 | 0,00 % | |||
| LENZ THERAPEUTICS | 9,395 | 0,00 | 0,00 % |
| Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
|---|---|---|---|---|---|
| 10X GENOMICS INC A2PPQJ Tradegate | 17,610 17,306 | +0,304 +1,76 % | 12:55 | ||
| 4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 8,940 8,830 | +0,110 +1,25 % | 16:52 | ||
| AARDVARK THERAPEUTICS INC A412BL NASDAQ | 5,095 5,050 | +0,045 +0,89 % | 15:55 | ||
| ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 3,330 3,285 | +0,045 +1,37 % | 16:51 | ||
| ABIVAX SA ADR A3EWCP Tradegate | 92,500 94,00 | +1,00 +1,09 % | 29.04. | ||
| ABSCI CORPORATION A3CVW3 NASDAQ | 4,990 4,710 | +0,280 +5,94 % | 16:52 | ||
| AC IMMUNE SA A2AR5F Tradegate | 2,735 2,520 | +0,215 +8,53 % | 14:23 | ||
| ACADIA PHARMACEUTICALS INC 603035 Tradegate | 19,375 18,745 | +0,365 +1,92 % | 27.04. | ||
| ACLARIS THERAPEUTICS INC A1412H Tradegate | 3,882 3,834 | +0,048 +1,25 % | 11:30 | ||
| ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 11,685 11,995 | +0,090 +0,78 % | 29.04. |